Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network

We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963...

Descripción completa

Detalles Bibliográficos
Autores: Rose, Angela Mc, Pozo Sanchez, Francisco, Martínez-Baz, Iván, Mazagatos, Clara, Bossuyt, Nathalie, Cauchi, John Paul, Petrović, Goranka, Loghin, Isabela I, Vaikutytė, Roberta, Buda, Silke, Machado, Ausenda, Duffy, Róisín, Oroszi, Beatrix, Howard, Jennifer, Echeverria, Aitziber, Andreu, Cristina, Barbezange, Cyril, Džiugytė, Aušra, Nonković, Diana, Popescu, Corneliu-Petru, Majauskaite, Fausta, Tolksdorf, Kristin, Gomez, Verónica, Domegan, Lisa, Horváth, Judit Krisztina, Castilla, Jesús, García, Miriam, Demuyser, Thomas, Borg, Maria-Louise, Tabain, Irena, Lazar, Mihaela, Kubiliute, Ieva, Dürrwald, Ralf, Guiomar, Raquel, O'Donnell, Joan, Kristóf, Katalin, Nicolay, Nathalie, Bacci, Sabrina, Kissling, Esther, EBIS SARI VE network team
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Instituto de Salud Carlos III (ISCIII)
Repositorio:Repisalud
Idioma:inglés
OAI Identifier:oai:repisalud.isciii.es:20.500.12105/19060
Acceso en línea:http://hdl.handle.net/20.500.12105/19060
Access Level:acceso abierto
Palabra clave:Influenza, Human
Influenza A Virus, H1N1 Subtype
Influenza Vaccines
Pneumonia
Adult
Humans
Seasons
Influenza A Virus, H3N2 Subtype
Case-Control Studies
Vaccine Efficacy
Europe
Hospitalization
Hospitals
Vaccination
Descripción
Sumario:We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.

Similares en LA Referencia